366 related articles for article (PubMed ID: 35046943)
1. Spatial Distribution and Predictive Significance of Dendritic Cells and Macrophages in Esophageal Cancer Treated With Combined Chemoradiotherapy and PD-1 Blockade.
Ma X; Guo Z; Wei X; Zhao G; Han D; Zhang T; Chen X; Cao F; Dong J; Zhao L; Yuan Z; Wang P; Pang Q; Yan C; Zhang W
Front Immunol; 2021; 12():786429. PubMed ID: 35046943
[TBL] [Abstract][Full Text] [Related]
2. Spatial distribution of tumor-infiltrating T cells indicated immune response status under chemoradiotherapy plus PD-1 blockade in esophageal cancer.
Yan C; Huang H; Zheng Z; Ma X; Zhao G; Zhang T; Chen X; Cao F; Wei H; Dong J; Tang P; Jiang H; Wang M; Wang P; Pang Q; Zhang W
Front Immunol; 2023; 14():1138054. PubMed ID: 37275884
[TBL] [Abstract][Full Text] [Related]
3. RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma.
Yu R; Wang W; Li T; Li J; Zhao K; Wang W; Liang L; Wu H; Ai T; Huang W; Li L; Yu W; Wei C; Wang Y; Shen W; Xiao Z
Future Oncol; 2021 Nov; 17(31):4081-4089. PubMed ID: 34269067
[TBL] [Abstract][Full Text] [Related]
4. Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma.
Park S; Joung JG; Min YW; Nam JY; Ryu D; Oh D; Park WY; Lee SH; Choi Y; Ahn JS; Ahn MJ; Park K; Sun JM
J Immunother Cancer; 2019 May; 7(1):128. PubMed ID: 31097034
[TBL] [Abstract][Full Text] [Related]
5. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
6. Addition of camrelizumab to docetaxel, cisplatin, and radiation therapy in patients with locally advanced esophageal squamous cell carcinoma: a phase 1b study.
Zhang W; Yan C; Zhang T; Chen X; Dong J; Zhao J; Han D; Wang J; Zhao G; Cao F; Zhou D; Jiang H; Tang P; Zhao L; Yuan Z; Wang Q; Wang P; Pang Q
Oncoimmunology; 2021; 10(1):1971418. PubMed ID: 34616588
[TBL] [Abstract][Full Text] [Related]
7. Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial.
Zhang G; Yuan J; Pan C; Xu Q; Cui X; Zhang J; Liu M; Song Z; Wu L; Wu D; Luo H; Hu Y; Jiao S; Yang B
EBioMedicine; 2023 Apr; 90():104515. PubMed ID: 36921563
[TBL] [Abstract][Full Text] [Related]
8. Safety and Feasibility of Radiotherapy Plus Camrelizumab for Locally Advanced Esophageal Squamous Cell Carcinoma.
Zhang W; Yan C; Gao X; Li X; Cao F; Zhao G; Zhao J; Er P; Zhang T; Chen X; Wang Y; Jiang Y; Wang Q; Zhang B; Qian D; Wang J; Zhou D; Ren X; Yu Z; Zhao L; Yuan Z; Wang P; Pang Q
Oncologist; 2021 Jul; 26(7):e1110-e1124. PubMed ID: 33893689
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma.
Jiang Y; Lo AWI; Wong A; Chen W; Wang Y; Lin L; Xu J
Oncotarget; 2017 May; 8(18):30175-30189. PubMed ID: 28404915
[TBL] [Abstract][Full Text] [Related]
10. CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis.
Yang H; Zhang Q; Xu M; Wang L; Chen X; Feng Y; Li Y; Zhang X; Cui W; Jia X
Mol Cancer; 2020 Feb; 19(1):41. PubMed ID: 32103760
[TBL] [Abstract][Full Text] [Related]
11. Durvalumab and tremelimumab with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
Park S; Oh D; Choi YL; Chi SA; Kim K; Ahn MJ; Sun JM
Cancer; 2022 Jun; 128(11):2148-2158. PubMed ID: 35319779
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of PD-L1 expression on immune cells or tumor cells for locally advanced esophageal squamous cell carcinoma in patients treated with neoadjuvant chemoradiotherapy.
Huang TC; Liang CW; Li YI; Guo JC; Lin CC; Chen YJ; Cheng AL; Hsu CH
J Cancer Res Clin Oncol; 2022 Jul; 148(7):1803-1811. PubMed ID: 34432128
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of signal regulatory protein alpha (SIRPα) expression in esophageal squamous cell carcinoma.
Koga N; Hu Q; Sakai A; Takada K; Nakanishi R; Hisamatsu Y; Ando K; Kimura Y; Oki E; Oda Y; Mori M
Cancer Sci; 2021 Aug; 112(8):3018-3028. PubMed ID: 34009732
[TBL] [Abstract][Full Text] [Related]
14. To develop a prognostic model for neoadjuvant immunochemotherapy efficacy in esophageal squamous cell carcinoma by analyzing the immune microenvironment.
Yehan Z; Sheng Q; Hong Y; Jiayu L; Jun H; Juan J; Min S; Jiaxin Y; Shangzhi H; Yi W; Qifeng W; Xuefeng L; Wenwu H; Xueyan C; Yang L; Zongyao H
Front Immunol; 2024; 15():1312380. PubMed ID: 38726002
[TBL] [Abstract][Full Text] [Related]
15. Tackling Esophageal Squamous Cell Carcinoma with ITFn-Pt(IV): A Novel Fusion of PD-L1 Blockade, Chemotherapy, and T-cell Activation.
Xin Q; Wang D; Wang S; Zhang L; Liang Q; Yan X; Fan K; Jiang B
Adv Healthc Mater; 2024 Apr; 13(11):e2303623. PubMed ID: 38142309
[TBL] [Abstract][Full Text] [Related]
16. Time-spatial analysis of T cell receptor repertoire in esophageal squamous cell carcinoma patients treated with combined radiotherapy and PD-1 blockade.
Yan C; Ma X; Guo Z; Wei X; Han D; Zhang T; Chen X; Cao F; Dong J; Zhao G; Gao X; Wang T; Jiang Y; Wang P; Pang Q; Zhang W
Oncoimmunology; 2022; 11(1):2025668. PubMed ID: 35036077
[TBL] [Abstract][Full Text] [Related]
17. Refractory solitary cervical lymph node metastasis after esophageal squamous cell carcinoma surgery and its successful treatment with immune checkpoint inhibitor: A case report and literature review.
Song W; Wang H; Tian Y; Liu S; Chen X; Cui J; Zhao Y
Medicine (Baltimore); 2020 Mar; 99(10):e19440. PubMed ID: 32150096
[TBL] [Abstract][Full Text] [Related]
18. Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma.
Baba Y; Nomoto D; Okadome K; Ishimoto T; Iwatsuki M; Miyamoto Y; Yoshida N; Baba H
Cancer Sci; 2020 Sep; 111(9):3132-3141. PubMed ID: 32579769
[TBL] [Abstract][Full Text] [Related]
19. Optimal preoperative neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma.
Leng XF; Daiko H; Han YT; Mao YS
Ann N Y Acad Sci; 2020 Dec; 1482(1):213-224. PubMed ID: 33067818
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 expression, CD8+ and CD4+ lymphocyte rate are predictive of pathological complete response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic esophagus.
Fassan M; Cavallin F; Guzzardo V; Kotsafti A; Scarpa M; Cagol M; Chiarion-Sileni V; Maria Saadeh L; Alfieri R; Castagliuolo I; Rugge M; Castoro C; Scarpa M
Cancer Med; 2019 Oct; 8(13):6036-6048. PubMed ID: 31429521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
